Nexalin Technology announced it has closed the acquisition of PONM, an AI-integrated digital health platform that powers the company’s HALO™ Clarity program and Nexalin NeuroCare™ virtual clinic. Nexalin said the deal gives it ownership and an exclusive license to software features that support AI-enabled remote patient monitoring, treatment-compliance data capture, electronic health record functionality, virtual-clinic management, and real-time analytics.

The U.S. Small Business Administration (SBA) announced a new rule that doubles the cumulative borrowing limit for its two flagship small-business loan programs—7(a) and 504—allowing eligible borrowers to access up to $10 million in total SBA-backed financing. The change is effective July 4, 2026 and increases the combined cap from the previous $5 million level.

Vermont lawmakers are moving to draw a clear line between helpful administrative automation and AI acting as a mental health clinician. In a May 7 VTDigger report, the Vermont Senate advanced H.816, a bill designed to ensure that licensed mental health professionals — not AI chatbots — make diagnoses, treatment plans, and therapeutic decisions in the state. Supporters say the legislation responds to the rapid growth of online “wellness” chatbots that can blur into clinical territory, potentially offering diagnosis-like statements or treatment guidance without appropriate oversight.

How does GLP-1 use impact psychological wellbeing in adults with diabetes and obesity? A recent study published in JAMA Psychiatry sought to understand this relationship. The connection between depression and diabetes/obesity is well-established and goes both ways; individuals with diabetes are more likely to report feeling depressed, and individuals with depression are more likely to develop obesity.

By Marlana Dant and Krystal Scharon
Featuring insights from Stephen Bungay, Senior Director of Sales at Schlegal Villages

At this year’s Senior Living Executive Conference (SLEC), attendees will have the opportunity to experience something truly different, a session that goes beyond strategy and operations and instead taps into the heart of why senior living exists: human connection.

The U.S. Drug Enforcement Administration (DEA) has issued a new Public Safety Advisory warning communities, healthcare professionals, first responders, and law enforcement agencies about the growing threat of illicit synthetic opioids and emerging fentanyl-related substances circulating throughout the United States. The advisory highlights the increasing presence of highly potent synthetic drugs mixed into counterfeit pills, heroin, cocaine, and other street narcotics—often without the user’s knowledge—dramatically increasing the risk of overdose and death.

New research suggests that Wegovy, the popular semaglutide-based weight-loss medication, may also help reduce alcohol consumption among people with alcohol use disorder (AUD). In a first-of-its-kind randomized controlled trial conducted in Denmark, adults with both obesity and AUD who received weekly semaglutide injections reported significantly fewer heavy drinking days compared with participants receiving a placebo.

The U.S. Drug Enforcement Administration (DEA) has issued a new Public Safety Advisory warning communities, healthcare professionals, first responders, and law enforcement agencies about the growing threat of illicit synthetic opioids and emerging fentanyl-related substances circulating throughout the United States. The advisory highlights the increasing presence of highly potent synthetic drugs mixed into counterfeit pills, heroin, cocaine, and other street narcotics—often without the user’s knowledge—dramatically increasing the risk of overdose and death.

The U.S. Drug Enforcement Administration (DEA) has issued a new Public Safety Advisory warning communities, healthcare professionals, first responders, and law enforcement agencies about the growing threat of illicit synthetic opioids and emerging fentanyl-related substances circulating throughout the United States. The advisory highlights the increasing presence of highly potent synthetic drugs mixed into counterfeit pills, heroin, cocaine, and other street narcotics—often without the user’s knowledge—dramatically increasing the risk of overdose and death.